Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: A window for adoptive immunotherapy

Journal of Immunology

Volumn 184, Issue 2, 2010, Pages 1079-1084

  Condomines, Maud ^a,b,c   Veyrune, Jean Luc ^a   Larroque, Marion ^a   Quittet, Philippe ^a   Latry, Pascal ^a   Lugagne, Cécile ^a   Hertogh, Catherine ^a   Kanouni, Tarik ^a   Rossi, Jean François ^a,c   Klein, Bernard ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; MELPHALAN; IMMUNOLOGIC FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MONOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; AUTOTRANSPLANTATION; BLOOD; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KINETICS; LYMPHOCYTE DEPLETION; METHODOLOGY; MIDDLE AGED;

CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; KINETICS; LYMPHOCYTE DEPLETION; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 76249097336     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804159     Document Type: Article

References (47)

1. Attal, M., J. L. Harousseau, A. M. Stoppa, J. J. Sotto, J. G. Fuzibet, J. F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, et al. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N. Engl. J. Med. 335: 91-97.
2. Guillaume, T., D. B. Rubinstein, and M. Symann. 1998. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92: 1471-1490. (Pubitemid 28406849)
3. Nordøy, T., A. Husebekk, I. S. Aaberge, P. A. Jenum, H. H. Samdal, L. B. Flugsrud, A. C. Kristoffersen, H. Holte, S. Kvaløy, and A. Kolstad. 2001. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 28: 681-687.
4. Hakim, F. T., S. A. Memon, R. Cepeda, E. C. Jones, C. K. Chow, C. Kasten-Sportes, J. Odom, B. A. Vance, B. L. Christensen, C. L. Mackall, et al. 2005. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115: 930-939.
5. Rutella, S., L. Pierelli, G. Bonanno, A. Mariotti, S. Sica, F. Sorà, P. Chiusolo, G. Scambia, C. Rumi, and G. Leone. 2001. Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp. Hematol. 29: 1503-1516.
6. Lindemann, M., P. Schuett, T. Moritz, H. D. Ottinger, B. Opalka, S. Seeber, M. R. Nowrousian, and H. Grosse-Wilde. 2005. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia 19: 490-492.
7. van der Velden, A. M., A. M. Claessen, H. van Velzen-Blad, D. H. Biesma, and G. T. Rijkers. 2007. Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of γ-interferon. Bone Marrow Transplant. 40: 261-266.
8. Mackall,C. L.,T.A. Fleisher, M.R. Brown,M. P.Andrich, C. C. Chen, I.M. Feuerstein, M. E. Horowitz, I. T. Magrath, A. T. Shad, S. M. Steinberg, et al. 1995. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332: 143-149.
9. Bomberger, C., M. Singh-Jairam, G. Rodey, A. Guerriero, A. M. Yeager, W. H. Fleming, H. K. Holland, and E. K. Waller. 1998. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 91: 2588-2600.
10. Douek, D. C., R. A. Vescio, M. R. Betts, J. M. Brenchley, B. J. Hill, L. Zhang, J. R. Berenson, R. H. Collins, and R. A. Koup. 2000. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 355: 1875-1881.
11. Mackall, C. L., T. A. Fleisher, M. R. Brown, M. P. Andrich, C. C. Chen, I. M. Feuerstein, I. T. Magrath, L. H. Wexler, D. S. Dimitrov, and R. E. Gress. 1997. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 89: 3700-3707.
12. Williams, K. M., F. T. Hakim, and R. E. Gress. 2007. T cell immune reconstitution following lymphodepletion. Semin. Immunol. 19: 318-330.
13. Porrata, L. F., M. A. Gertz, D. J. Inwards, M. R. Litzow, M. Q. Lacy, A. Tefferi, D. A. Gastineau, A. Dispenzieri, S. M. Ansell, I. N. Micallef, et al. 2001. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98: 579-585.
14. Porrata, L. F., M. A. Gertz, S. M. Geyer, M. R. Litzow, D. A. Gastineau, S. B. Moore, A. A. Pineda, K. L. Bundy, D. J. Padley, D. Persky, et al. 2004. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 18: 1085-1092.
15. Condomines, M., P. Quittet, Z. Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J. F. Schved, et al. 2006. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J. Immunol. 176: 6631-6639.
16. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
17. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
18. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
19. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501.
20. Rapoport, A. P., E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11: 1230-1237.
21. Rossi, J. F., N. Fegueux, Z. Y. Lu, E. Legouffe, C. Exbrayat, M. C. Bozonnat, R. Navarro, E. Lopez, P. Quittet, J. P. Daures, et al. 2005. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 36: 771-779.
22. Vescio, R., G. Schiller, A. K. Stewart, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadtmauer, S. Tarantolo, F. Sahebi, et al. 1999. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 93: 1858-1868. (Pubitemid 29128487)
23. Steffen, M., M. Dürken, U. Pichlmeier, C. von dem Busche, M. Stockschläder, W. Krüger, C. Budde-Steffen, and A. Zander. 1996. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and engraftment. Bone Marrow Transplant. 18: 301-307.
24. Shi, J., G. Tricot, S. Szmania, N. Rosen, T. K. Garg, P. A. Malaviarachchi, A. Moreno, B. Dupont, K. C. Hsu, L. A. Baxter-Lowe, et al. 2008. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143: 641-653.
25. Bolotin, E., G. Annett, R. Parkman, and K.Weinberg. 1999. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23: 783-788.
26. Chik, K. W., K. Li, H. Pong, M. M. Shing, C. K. Li, and P. M. Yuen. 2003. Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation. J. Pediatr. Hematol. Oncol. 25: 960-964.
27. Klein, B., X.G. Zhang, M. Jourdan, J. M. Boiron,M. Portier, Z.Y. Lu, J.Wijdenes, J. Brochier, and R. Bataille. 1990. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Netw. 1: 193-201.
28. Weber, J., J. C. Yang, S. L. Topalian, D. R. Parkinson, D. S. Schwartzentruber, S. E. Ettinghausen, H. Gunn, A. Mixon, H. Kim, D. Cole, et al. 1993. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 11: 499-506.
29. Wang, L. X., S. Shu, and G. E. Plautz. 2005. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 65: 9547-9554.
30. Kobayashi, A., H. Hara, M. Ohashi, T. Nishimoto, K. Yoshida, N. Ohkohchi, T. Yoshida, and K. Aoki. 2007. Allogeneic MHC gene transfer enhances an effective antitumor immunity in the early period of autologous hematopoietic stem cell transplantation. Clin. Cancer Res. 13: 7469-7479.
31. Suzuki, T., S. Ogawa, K. Tanabe, H. Tahara, R. Abe, and H. Kishimoto. 2008. Induction of antitumor immune response by homeostatic proliferation and CD28 signaling. J. Immunol. 180: 4596-4605.
32. Brody, J. D., M. J. Goldstein, D. K. Czerwinski, and R. Levy. 2008. Immunotransplant preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood.11:85-94.
33. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
34. Wallen, H., J. A. Thompson, J. Z. Reilly, R. M. Rodmyre, J. Cao, and C. Yee. 2009. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 4: e4749.
35. Laport, G. G., B. L. Levine, E. A. Stadtmauer, S. J. Schuster, S. M. Luger, S. Grupp, N. Bunin, F. J. Strobl, J. Cotte, Z. Zheng, et al. 2003. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102: 2004-2013.
36. Boyman, O., J. F. Purton, C. D. Surh, and J. Sprent. 2007. Cytokines and T-cell homeostasis. Curr. Opin. Immunol. 19: 320-326.
37. Sandau, M. M., C. J. Winstead, and S. C. Jameson. 2007. IL-15 is required for sustained lymphopenia-driven proliferation and accumulation of CD8 T cells. J. Immunol. 179: 120-125.
38. Baccala, R., D. Witherden, R. Gonzalez-Quintial, W. Dummer, C. D. Surh, W. L. Havran, and A. N. Theofilopoulos. 2005. g d T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J. Immunol. 174: 4606-4612. (Pubitemid 40504541)
39. Burjanadzé, M., M. Condomines, T. Reme, P. Quittet, P. Latry, C. Lugagne, F. Romagne, Y. Morel, J. F. Rossi, B. Klein, and Z. Y. Lu. 2007. In vitro expansion of γ δ T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br. J. Haematol. 139: 206-216.
40. Jalili, A., S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto. 2005. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 106: 3538-3545.
41. Hundemer, M., S. Schmidt, M. Condomines, A. Lupu, D. Hose, M. Moos, F. Cremer, C. Kleist, P. Terness, S. Belle, et al. 2006. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp. Hematol. 34: 486-496.
42. Choi, C., M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, and P. Beckhove. 2005. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105: 2132-2134.
43. Goodyear, O., K. Piper, N. Khan, J. Starczynski, P. Mahendra, G. Pratt, and P. Moss. 2005. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106: 4217-4224.
44. van Rhee, F., S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, and J. Shaughnessy, et al. 2005. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105: 3939-3944.
45. Condomines, M., D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J. F. Schved, et al. 2007. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J. Immunol. 178: 3307-3315.
46. Belle, S., F. Han, M. Condomines, O. Christensen, M. Witzens-Harig, B. Kasper, C. Kleist, P. Terness, M. Moos, F. Cremer, et al. 2008. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma. Eur. J. Haematol. 81: 26-35.
47. Tarte, K., and B. Klein. 1999. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13: 653-663. (Pubitemid 29243614)